Mind Medicine SEC Filings

Mind Medicine (MindMed) Inc. (MNMD) – Form 4 insider transaction:

Chief Legal Officer Mark Sullivan reported the sale of 11,491 common shares on 25-Jun-2025. The shares were automatically sold (transaction code “S”) to cover withholding-tax liabilities triggered by the settlement of vested RSUs. The disposition was executed under a Rule 10b5-1 plan adopted 14-Mar-2024, indicating the trade was pre-scheduled and not discretionary.

The weighted-average sales price was $6.80, with individual trades carried out between $6.67 and $7.03. After the sale, Sullivan directly owns 305,130 shares, meaning the transaction reduced his position by roughly 3.6 %. No derivative securities were involved, and the filing was signed on 26-Jun-2025.

• The activity appears routine, tax-driven and represents a small fraction of the executive’s holdings.
• Provides investors with an indicative trading range for MNMD at the end of June 2025.

Given the limited size and tax-related nature, the sale is unlikely to carry significant fundamental implications, though it is the first insider disposition tied to this RSU vesting cycle.

MindMed (NASDAQ: MNMD) filed a Form 4 showing CEO & Director Robert Barrow sold 26,491 common shares on 25 Jun 2025 at a weighted-average price of $6.80. The sale, made under a pre-arranged Rule 10b5-1 plan, was solely to cover withholding taxes on recently vested RSUs. After the transaction, Barrow retains 830,065 shares of MindMed. No other insider trades or material changes were disclosed.

A Form 144 filing from Mind Medicine (MindMed) indicates a proposed sale of 7,848 shares of common stock with an aggregate market value of $53,387.59 by an insider. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ exchange, with an approximate sale date of June 25, 2025.

The securities were originally acquired through restricted stock vesting under a registered plan as compensation on June 25, 2025. The total outstanding shares of the company are reported at 75,553,266.

• Share Price (implied): ~$6.80 per share
• Sale represents approximately 0.01% of total outstanding shares
• No other securities were reported as sold by the insider during the past 3 months

Form 144 is required for proposed sales of restricted securities by affiliates, indicating this is likely an insider or executive transaction.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has filed a Form S-8 to register up to 16,367,773 additional common shares for employee equity compensation programs. The filing covers three components:

• 2025 Equity Incentive Plan: 4,500,000 newly reserved shares plus up to 9,318,090 "Outstanding Award Shares" that could migrate from retired legacy plans if the underlying awards are forfeited or lapse.
• Performance & Restricted Share Unit (PRSU) Plan: 147,133 shares for ongoing PSU/RSU grants under the existing PRSU plan.
• Inducement Grants: 2,402,550 shares for option, RSU and PSU awards issued to new hires under Nasdaq Listing Rule 5635(c)(4).

The Board approved the 2025 Plan on 22 April 2025 and shareholders ratified it on 12 June 2025. The registration enables the company to issue shares quickly when awards vest or options are exercised, without additional SEC registration hurdles. Standard incorporation-by-reference language brings the company’s latest 10-K, 10-Q and specified 8-Ks into the prospectus, and the filing reiterates indemnification provisions for directors and officers under British Columbia law.

Key investor takeaway: The registration itself does not raise capital but it does increase the pool of shares that can enter the market through employee exercises or vesting, representing potential dilution of approximately 4.8 % of the 338 million shares outstanding as of the last 10-Q (not included in the filing but cited here for context). The expanded equity capacity is intended to support talent attraction and retention during the company’s clinical development phase.